Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A.

Simple item page
dc.citation.volume14
dc.contributor.authorHarjes S
dc.contributor.authorKurup HM
dc.contributor.authorRieffer AE
dc.contributor.authorBayaijargal M
dc.contributor.authorFilitcheva J
dc.contributor.authorSu Y
dc.contributor.authorHale TK
dc.contributor.authorFilichev VV
dc.contributor.authorHarjes E
dc.contributor.authorHarris RS
dc.contributor.authorJameson GB
dc.coverage.spatialUnited States
dc.date.accessioned2024-07-24T02:21:16Z
dc.date.available2024-07-24T02:21:16Z
dc.date.issued2023-02-17
dc.description.abstractThe normally antiviral enzyme APOBEC3A1-4 is an endogenous mutagen in many different human cancers5-7, where it becomes hijacked to fuel tumor evolvability. APOBEC3A's single-stranded DNA C-to-U editing activity1,8 results in multiple mutagenic outcomes including signature single-base substitution mutations (isolated and clustered), DNA breakage, and larger-scale chromosomal aberrations5-7. Transgenic expression in mice demonstrates its tumorigenic potential9. APOBEC3A inhibitors may therefore comprise a novel class of anti-cancer agents that work by blocking mutagenesis, preventing tumor evolvability, and lessening detrimental outcomes such as drug resistance and metastasis. Here we reveal the structural basis of competitive inhibition of wildtype APOBEC3A by hairpin DNA bearing 2'-deoxy-5-fluorozebularine in place of the cytidine in the TC recognition motif that is part of a three-nucleotide loop. The nuclease-resistant phosphorothioated derivatives of these inhibitors maintain nanomolar in vitro potency against APOBEC3A, localize to the cell nucleus, and block APOBEC3A activity in human cells. These results combine to suggest roles for these inhibitors to study A3A activity in living cells, potentially as conjuvants, leading toward next-generation, combinatorial anti-mutator and anti-cancer therapies.
dc.description.confidentialfalse
dc.edition.edition2023
dc.identifier.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36824964
dc.identifier.citationHarjes S, Kurup HM, Rieffer AE, Bayaijargal M, Filitcheva J, Su Y, Hale TK, Filichev VV, Harjes E, Harris RS, Jameson GB. (2023). Structure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A.. bioRxiv. 14.
dc.identifier.doi10.1101/2023.02.17.528918
dc.identifier.eissn2692-8205
dc.identifier.elements-typejournal-article
dc.identifier.number6382
dc.identifier.pii2023.02.17.528918
dc.identifier.urihttps://mro.massey.ac.nz/handle/10179/70313
dc.languageeng
dc.publisherSpringer Nature Limited
dc.publisher.urihttps://www.nature.com/articles/s41467-023-42174-w
dc.relation.isPartOfbioRxiv
dc.rights(c) 2023 The Author/s
dc.rightsCC BY 4.0
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAPOBEC3A
dc.subjectDNA mutagenesis
dc.subjectcancer
dc.subjecttumor evolvability
dc.titleStructure-guided inhibition of the cancer DNA-mutating enzyme APOBEC3A.
dc.typeJournal article
pubs.elements-id459899
pubs.organisational-groupOther
Files
Original bundle
Now showing 1 - 4 of 4
Thumbnail Image
Name:
Published version.pdf
Size:
3.18 MB
Format:
Adobe Portable Document Format
Description:
459899 PDF.pdf
Download
Thumbnail Image
Name:
Evidence 3.pdf
Size:
3.46 MB
Format:
Adobe Portable Document Format
Description:
41467_2023_42174_MOESM1_ESM (1).pdf
Download
Thumbnail Image
Name:
Evidence 1.pdf
Size:
495.1 KB
Format:
Adobe Portable Document Format
Description:
41467_2023_42174_MOESM2_ESM (1).pdf
Download
Thumbnail Image
Name:
Evidence 2.pdf
Size:
279.06 KB
Format:
Adobe Portable Document Format
Description:
41467_2023_42174_MOESM3_ESM (1).pdf
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
9.22 KB
Format:
Plain Text
Description:
Download
Collections
Journal Articles